TME Pharma N.V.
ALTME.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.03 |
| FCF Yield | -226.71% | -489.89% | -847.83% | -80.38% |
| EV / EBITDA | 0.22 | -0.01 | -0.08 | -0.65 |
| Quality | ||||
| ROIC | -315.99% | -645.15% | -427.67% | -191.13% |
| Gross Margin | -410.53% | -747.06% | 0.00% | -199.90% |
| Cash Conversion Ratio | 0.81 | 0.84 | 0.80 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -19.84% | -100.00% | 498.41% |
| Free Cash Flow Growth | 17.76% | 53.52% | 1.86% | -135.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.61 | 0.21 | 0.05 | 0.54 |
| Interest Coverage | -10.49 | -3.70 | -3.54 | -8.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.24 | 0.53 |
| Cash Conversion Cycle | -5,705.53 | -2,077.73 | -6,431.14 | -10,778.56 |